ES2188637T3 - Preparacion de cristales estables de zinc analogos a la insulina. - Google Patents

Preparacion de cristales estables de zinc analogos a la insulina.

Info

Publication number
ES2188637T3
ES2188637T3 ES95304098T ES95304098T ES2188637T3 ES 2188637 T3 ES2188637 T3 ES 2188637T3 ES 95304098 T ES95304098 T ES 95304098T ES 95304098 T ES95304098 T ES 95304098T ES 2188637 T3 ES2188637 T3 ES 2188637T3
Authority
ES
Spain
Prior art keywords
insulin
preparation
stable crystals
sup
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95304098T
Other languages
English (en)
Inventor
Jeffrey Clayton Baker
Nancy Delores Carter
Bruce Hill Frank
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22990041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2188637(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2188637T3 publication Critical patent/ES2188637T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

EN LA PRESENTE INVENCION SE PRESENTA UN PROCESO PARA LA PREPARACION DE UN ANALOGO DE INSULINA CRISTALINO. EL PROCESO ES UTIL PARA LA PURIFICACION Y FABRICACION DE INSULINA HUMANA LYS{SUP,B28}PRO{SUP,B29}. LA INSULINA HUMANA LYS{SUP,B28}PRO{SUP,B29} ES UTIL PARA EL TRATAMIENTO DE LA DIABETES.
ES95304098T 1994-06-16 1995-06-14 Preparacion de cristales estables de zinc analogos a la insulina. Expired - Lifetime ES2188637T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,647 US5504188A (en) 1994-06-16 1994-06-16 Preparation of stable zinc insulin analog crystals

Publications (1)

Publication Number Publication Date
ES2188637T3 true ES2188637T3 (es) 2003-07-01

Family

ID=22990041

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95304098T Expired - Lifetime ES2188637T3 (es) 1994-06-16 1995-06-14 Preparacion de cristales estables de zinc analogos a la insulina.

Country Status (29)

Country Link
US (1) US5504188A (es)
EP (1) EP0692489B1 (es)
JP (1) JP3595607B2 (es)
KR (1) KR100369951B1 (es)
CN (1) CN1184234C (es)
AT (1) ATE233278T1 (es)
AU (1) AU697794B2 (es)
BR (1) BR9502798A (es)
CA (1) CA2151563C (es)
CO (1) CO4410205A1 (es)
CZ (1) CZ286066B6 (es)
DE (1) DE69529708T2 (es)
DK (1) DK0692489T3 (es)
ES (1) ES2188637T3 (es)
FI (1) FI952930A7 (es)
HU (1) HUT73495A (es)
IL (1) IL114152A (es)
IN (1) IN178919B (es)
MY (1) MY130551A (es)
NO (1) NO952334L (es)
NZ (1) NZ272358A (es)
PE (1) PE21896A1 (es)
PL (1) PL180968B1 (es)
RO (1) RO113529B1 (es)
RU (1) RU2156257C2 (es)
SI (1) SI0692489T1 (es)
TW (1) TW379228B (es)
YU (1) YU39595A (es)
ZA (1) ZA954942B (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5869604A (en) * 1995-11-09 1999-02-09 Georgia Institute Of Technology Crystallization and purification of polypeptides
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
JP2001518915A (ja) * 1997-03-20 2001-10-16 ノボ ノルディスク アクティーゼルスカブ インシュリンと吸収増強剤の共沈殿による治療用粉末の調整法
ES2230727T3 (es) * 1997-11-12 2005-05-01 Alza Corporation Procedimiento de administracion dermal de polipeptidos.
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
DK1121145T3 (da) * 1998-10-16 2002-08-12 Novo Nordisk As Insulinpræparater til indgivelse via lungerne, som indeholder mentol
UA65636C2 (uk) * 1998-10-16 2004-04-15 Ново Нордіск А/С Стабільні концентровані препарати інсуліну для доставки через легені
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
CN100439397C (zh) * 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
ATE482747T1 (de) 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
RU2527893C2 (ru) * 2004-07-19 2014-09-10 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
WO2006020580A2 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
EP1910317B1 (en) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
ES2393757T3 (es) 2005-11-17 2012-12-27 Eli Lilly & Company Antagonistas de receptor de glucagón, preparación y usos terapéuticos
EP1996224B1 (en) 2006-03-15 2012-11-07 Novo Nordisk A/S Mixtures of amylin and insulin
CN101410385B (zh) 2006-03-28 2011-08-24 高点制药有限责任公司 具有组胺h3受体活性的苯并噻唑类
WO2007121318A2 (en) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
EA016415B1 (ru) 2006-04-24 2012-04-30 Эли Лилли Энд Компани Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
EP2402324A1 (en) 2006-05-29 2012-01-04 High Point Pharmaceuticals, LLC Benzodioxolylcyclopropylpiperazinylpyridazines
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CN101677944A (zh) 2007-06-01 2010-03-24 诺沃-诺迪斯克有限公司 稳定的非含水药物组合物
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
JP5552046B2 (ja) * 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
RU2453332C2 (ru) * 2007-10-16 2012-06-20 Байокон Лимитид Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
CN102202669A (zh) 2008-10-28 2011-09-28 利兰·斯坦福青年大学托管委员会 醛脱氢酶调节剂及其使用方法
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
BRPI1007457A2 (pt) 2009-01-28 2015-08-25 Smartcells Inc Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
US8623345B2 (en) 2009-03-20 2014-01-07 Smartcells Terminally-functionalized conjugates and uses thereof
CN102471368A (zh) * 2009-08-11 2012-05-23 拜康有限公司 色谱方法及其纯化的化合物
WO2012104339A1 (en) 2011-02-01 2012-08-09 Novo Nordisk A/S Purification of insulin
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CN103342746B (zh) * 2013-07-26 2014-07-30 珠海联邦制药股份有限公司 一种制备稳定的门冬胰岛素结晶的方法
US9822158B2 (en) 2013-12-04 2017-11-21 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
EP3185887B1 (en) 2014-08-26 2021-03-10 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
EP2990033A1 (fr) * 2014-08-26 2016-03-02 Carlina Technologies Procédé de préparation de nanoprécipites de peptide ou protéine de faible poids moléculaire
CN104193819B (zh) * 2014-09-03 2017-05-17 韩飞 胰岛素二聚体晶体的合成和保存方法
CN104761632A (zh) * 2015-04-14 2015-07-08 珠海联邦制药股份有限公司 一种地特胰岛素结晶的制备方法及应用
CN106117345B (zh) * 2015-05-05 2020-11-24 宜昌东阳光长江药业股份有限公司 一种制备甘精胰岛素结晶的方法
CN104892749B (zh) * 2015-06-16 2019-02-05 珠海联邦制药股份有限公司 一种德谷胰岛素结晶的制备方法及应用
CN105753966A (zh) * 2016-05-05 2016-07-13 通化东宝药业股份有限公司 一种重组人胰岛素结晶的制备方法
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
GB2610490A (en) 2020-03-31 2023-03-08 Protomer Tech Inc Conjugates for selective responsiveness to vicinal diols
IL302775A (en) 2020-11-19 2023-07-01 Protomer Tech Inc Aromatic boron-containing compounds and insulin analogs
CN113896784B (zh) * 2021-10-18 2024-04-16 合肥天麦生物科技发展有限公司 一种胰岛素结晶的制备方法及其产品
IL317049A (en) 2022-05-18 2025-01-01 Protomer Tech Inc Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE533252A (es) *
BE515508A (es) *
BE533298A (es) *
US2143590A (en) * 1936-09-26 1939-01-10 Univ Alberta Insulin preparation and process of producing crystals of insulin
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2920104A (en) 1958-07-01 1960-01-05 Vanderbilt Co R T Stabilized solutions of a dithiocarbamate
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
JPH03506023A (ja) * 1988-07-20 1991-12-26 ノボ　ノルデイスク　アクツイエセルスカプ ポリペプチド
HUT56857A (en) * 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
EP1132404A3 (en) * 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina

Also Published As

Publication number Publication date
FI952930L (fi) 1995-12-17
IL114152A (en) 1999-12-31
PL309099A1 (en) 1995-12-27
FI952930A0 (fi) 1995-06-14
FI952930A7 (fi) 1995-12-17
KR100369951B1 (ko) 2003-03-28
HU9501715D0 (en) 1995-08-28
IL114152A0 (en) 1995-10-31
DE69529708T2 (de) 2003-10-16
AU2168195A (en) 1996-01-04
NO952334L (no) 1995-12-18
CO4410205A1 (es) 1997-01-09
KR960000922A (ko) 1996-01-25
YU39595A (sh) 1997-08-22
RO113529B1 (ro) 1998-08-28
CN1128271A (zh) 1996-08-07
NZ272358A (en) 1996-12-20
EP0692489A1 (en) 1996-01-17
CA2151563A1 (en) 1995-12-17
CA2151563C (en) 2007-08-07
RU2156257C2 (ru) 2000-09-20
CZ286066B6 (cs) 2000-01-12
HUT73495A (en) 1996-08-28
JP3595607B2 (ja) 2004-12-02
TW379228B (en) 2000-01-11
US5504188A (en) 1996-04-02
ZA954942B (en) 1996-12-17
ATE233278T1 (de) 2003-03-15
IN178919B (es) 1997-07-19
DE69529708D1 (de) 2003-04-03
PL180968B1 (pl) 2001-05-31
SI0692489T1 (en) 2003-06-30
JPH08169899A (ja) 1996-07-02
AU697794B2 (en) 1998-10-15
RU95110107A (ru) 1997-05-10
CN1184234C (zh) 2005-01-12
BR9502798A (pt) 1996-06-04
EP0692489B1 (en) 2003-02-26
MY130551A (en) 2007-06-29
DK0692489T3 (da) 2003-03-31
NO952334D0 (no) 1995-06-13
PE21896A1 (es) 1996-06-15
CZ154195A3 (en) 1996-02-14

Similar Documents

Publication Publication Date Title
ES2188637T3 (es) Preparacion de cristales estables de zinc analogos a la insulina.
ATE135216T1 (de) Verwendung von spiperone-derivate zur immunosuppression
NZ229645A (en) Human des (32-65) proinsulin, pharmaceutical compositions, preparation by recombinant techniques and use in preparing insulin and insulin arg b31
ES2007607A6 (es) Un procedimiento para la obtencion de un preparado de insulina para la administracion no parenteral.
IL83668A (en) Transdermal therapeutic system, its use and process for the production thereof
BR9607647A (pt) Derivado de insulina e composição farmacêutica e processo para o tratamento de diabetes em um paciente em necessidade deste tratamento
JPH07500991A (ja) 薬物投与装置
MXPA04003553A (es) Mimeticos del peptido-1 similares aglucagon humano y su uso en tratamiento de diabetes y condiciones relacionadas.
ATE296131T1 (de) Vorrichtung zur verabreichung von medikamenten mit einem mikroprozessor und einem kennzeichenmonitor
ES2104697T3 (es) Formulados farmaceuticos.
WO2004094461A3 (en) Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
DE69226835D1 (de) Verfahren und zusammensetzungen zur behandlung von diabetes mellitus, hypoglykämie und anderer krankhafter zustände
CA1228540A (en) Process for the preparation of antispasmatic products to be fixed on the skin, in particular for the spasm of the muscles
AU4292585A (en) Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch
ATE416785T1 (de) Therapeutische anwendungen für c-peptid
DE68906513D1 (de) Topisch anzuwendende diclofenac enthaltende arzneizubereitungen.
George et al. An epidemic of Paederus dermatitis in southern Nigeria.
Ganapati et al. Field application of combined therapy for infectious leprosy cases. A feasibility study in Bombay
RU93007469A (ru) Способ лечения воспалительных заболеваний челюстно-лицевой области у больных сахарным диабетом
TH20759A (th) การเตรียมผลึกคล้ายอินซูลินกับสังกะสีที่เสถียร
KR20020070705A (ko) 인슐린 패치 착용장치